ticagrelor and abemaciclib

The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor that has recently demonstrated efficacy and safety in advanced breast cancer. Of major concern, however, reported thromboembolic rates in randomized clinical trials testing this drug range from 0.6 to 5%. To the best of our knowledge this is the first thrombotic coronary side effect ever reported. We suggest that a treatment that increases thromboembolic risk, such abemaciclib, may have triggered PE in our patient, 15 days after abemaciclib initiation. New molecules are promising in cancer treatment; however, care must be paid to their potential cardiotoxic effects.

Topics: Aged; Aminopyridines; Antineoplastic Agents; Artifacts; Benzimidazoles; Breast Neoplasms; Coronary Vessels; Enoxaparin; Female; Humans; Lipids; Myocardial Infarction; Protein Kinase Inhibitors; Thromboembolism; Ticagrelor; Treatment Outcome